leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...4243444546474849505152...235236»
  • ||||||||||  Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
    A confounding & masquerading tale of genital ulcers () -  Jul 3, 2023 - Abstract #WCD2023WCD_7058;    
    So, he was started on Famciclovir and topical imiquimod which led to resolution of lesions...We started him on Tab Leucovorin which led to dramatic improvement in the genital and skin lesions...Chronic methotrexate toxicity can present as mucositis and cutaneous ulceration without prompt pancytopenia. Early recognition and initiation of treatment is the mainstay
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  Proteomic Profiling of Chemotherapy Responses in FOLFOX-Resistant Colorectal Cancer Cells. (Pubmed Central) -  Jul 2, 2023   
    Up-regulations in the ribosome pathway (DLD1-R) and actin cytoskeleton (HCT116-R) were verified by Western blot. There were several significantly altered signaling pathways in FOLFOX-resistant colorectal cancer cells under FOLFOX with notable up-regulations in the ribosomal process and actin cytoskeleton.
  • ||||||||||  Review, Journal:  Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma. (Pubmed Central) -  Jul 1, 2023   
    In patients fit for intense chemotherapeutic regimens, FOLFIRINOX is associated with a lower BOTh than gem/erlotinib. While there are novel treatments being explored for metastatic pancreatic, it remains a debilitating and aggressive disease with high mortality that warrants continued efforts to advance therapeutic options.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion, Combination therapy, Metastases:  VITALITY: Vitamin C Intravenously With Chemotherapy in Advanced Colorectal Cancer (clinicaltrials.gov) -  Jun 27, 2023   
    P3,  N=442, Completed, 
    Trial completion date: Jun 2025 --> Dec 2024 | Trial primary completion date: Aug 2024 --> Dec 2024 Unknown status --> Completed
  • ||||||||||  Neurapeg (pegteograstim) / Green Cross Cell
    P3 data, Journal:  Comparison of prophylactic effects for chemotherapy induced neutropenia between same-day versus next-day administration of pegteograstim (Neurapeg (Pubmed Central) -  Jun 23, 2023   
    Administration of pegylated granulocyte-colony-stimulating factor (peg-GCSF) 24 to 72 hours after chemotherapy is usually recommended...Patients with adjuvant/neoadjuvant or first-line palliative chemotherapy comprising intensively myelosuppressive agents on day 1 (mFOLFIRINOX, ECb, EP, FOLFIRI, and FOLFOX) are enrolled...In order to verify non-inferiority of 0.6 days, we estimated a significance level of 5%, power of 80%, and drop-out rate of 15%. This results in the need for a total of 160 patients, 80 in each group.
  • ||||||||||  Opdivo (nivolumab) / BMS, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Trial completion date, Trial primary completion date:  Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov) -  Jun 23, 2023   
    P1/2,  N=34, Active, not recruiting, 
    Bevacizumab-based chemotherapy remains the preferable first-line treatment of patients with BRAF-mutant mCRC. Trial completion date: May 2023 --> May 2025 | Trial primary completion date: May 2023 --> May 2025
  • ||||||||||  Avastin (bevacizumab) / Roche, Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Retrospective data, Journal, PARP Biomarker, Metastases:  Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer. (Pubmed Central) -  Jun 21, 2023   
    Olaparib combined with bevacizumab in the treatment of advanced CRC demonstrates a strong clinical effect of delaying disease progression and reducing the serum levels of VEGF, MMP-9, COX-2 and tumor markers HE4, CA125 and CA199. Moreover, given its fewer adverse reactions, it can be regarded as a safe and reliable treatment option.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    TOLERABILITY, ATTRITION RATES, AND SURVIVAL OUTCOMES OF NEOADJUVANT FOLFIRINOX FOR NON-METASTATIC PANCREATIC ADENOCARCINOMA: AN INTENT-TO-TREAT ANALYSIS () -  Jun 20, 2023 - Abstract #APCM2023APCM_145;    
    Among 254 patients with non-metastatic PDAC initiated on FOLFIRINOX, of whom 52% were locally advanced, a total of 199 (78.3%) were explored, 142 (71.4%) underwent successful resection, and 129 (90.8%) were resected with negative margins. Despite 109 (42.9)% of patients experiencing significant toxicity, most patients could be managed through treatment-related complications to complete planned neoadjuvant chemotherapy and undergo planned surgical exploration.
  • ||||||||||  5-fluorouracil / Generic mfg.
    OPTIMAL PERIOPERATIVE MULTIAGENT CHEMOTHERAPY IN RESECTED PANCREATIC CANCER: A HIGH-VOLUME CENTER REPORT () -  Jun 20, 2023 - Abstract #APCM2023APCM_120;    
    Regarding neoadjuvant regimens, FOLFIRINOX was used in 224 patients (80%), while Gemcitabine/ Nab-paclitaxel was used in 56 patients (20%)... The results of this study suggest that most patient tolerate 4 cycles of neoadjuvant chemotherapy, with the best outcomes seen in patients treated with FOLFIRINOX, 6 or more cycles of chemotherapy, and CA 19-9 response regardless of resectability criteria.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    AGGRESSIVE MANAGEMENT OF ELDERLY PATIENTS WITH NON-METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (Monroe) -  Jun 20, 2023 - Abstract #APCM2023APCM_110;    
    Older patients with non-metastatic PDAC initiated on FOLFIRINOX with curative- intent experienced more toxicity-related emergency room visits and inpatient admissions and were less likely to complete their chemotherapy cycles when compared to younger patients. However, they were just as likely to undergo surgical exploration and resection and had similar adjusted survival outcomes when compared to younger patients, highlighting the feasibility of aggressive management of PDAC in elderly patients, including the use of neoadjuvant FOLFIRINOX.
  • ||||||||||  TOTAL NEOADJUVANT THERAPY FOR PANCREATIC CANCER: JUST WHAT ARE WE TALKING ABOUT? (Monroe) -  Jun 20, 2023 - Abstract #APCM2023APCM_102;    
    While some groups applied multi-agent chemotherapy alone (FOLFIRINOX or Gemcitabine/nab-paclitaxel), others combined such agents with additional drugs (Losartan), radiation (either before or after surgery), and/or adjuvant chemotherapy... The conceptual construct
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    STEREOTACTIC BODY RADIOTHERAPY AFTER INDUCTION CHEMOTHERAPY WITH (M)FOLFIRINOX IN PATIENTS WITH LOCALLY ADVANCED PANCREATIC CANCER  (Adams) -  Jun 20, 2023 - Abstract #APCM2023APCM_89;    
    In this retrospective cohort study, (m)FOLFIRINOX followed by stereotactic radiotherapy was associated with significantly favourable survival outcomes, compared to (m)FOLFIRINOX alone. Since the risk for immortal time bias in this study was considerable, these data warrants a future randomized trial to finally elucidate the possible role of stereotactic radiotherapy in the treatment of localized pancreatic cancer.
  • ||||||||||  Ampligen (rintatolimod) / AIM ImmunoTech
    IMMUNE RESPONSE IN STABLE PANCREATIC CANCER AFTER RINTATOLIMOD TREATMENT (Adams) -  Jun 20, 2023 - Abstract #APCM2023APCM_55;    
    The absence of these markers could predict tumor progression after FOLFIRINOX. Further identification of T lymphocyte and dendritic cell subsets using flow-cytometry analysis will be presented.